Veradermics, Inc
Veradermics, Inc
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | 2025-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|
Assets | ||||||||
Assets Current | ||||||||
Cash And Cash Equivalents At Carrying Value | 319 | 168 | 22 | |||||
Available For Sale Securities Debt Securities Curr… | 501 | 222 | 120 | |||||
Prepaid Expense And Other Assets Current | 5 | 6 | 11 | |||||
Assets Current | 825 | 397 | 152 | |||||
Assets Noncurrent | ||||||||
Property Plant And Equipment Net | 0 | 0 | 0 | |||||
Operating Lease Right Of Use Asset | 1 | 0 | 0 | |||||
Assets Noncurrent | 1 | 0 | 0 | |||||
Assets | 826 | 397 | 153 | |||||
Liabilities And Stockhold… | ||||||||
Liabilities Current | ||||||||
Accounts Payable Current | 6 | 1 | 2 | |||||
Accrued Liabilities Current | 5 | 6 | 7 | |||||
Other Liabilities Current | 0 | 0 | 0 | |||||
Liabilities Current | 12 | 7 | 9 | |||||
Operating Lease Liability Noncurrent | 0 | 0 | 0 | |||||
Liabilities | 12 | 7 | 9 | |||||
Temporary Equity | ||||||||
Temporary Equity Shares Subscribed But Unissued Su… | 0 | 0 | -2 | |||||
Stockholders Equity | ||||||||
Preferred Stock Value | 0 | 0 | - | |||||
Common Stock Value | 0 | 0 | 0 | |||||
Additional Paid In Capital | 989 | 543 | 2 | |||||
Stockholders Equity Note Subscriptions Receivable | -1 | -1 | - | |||||
Accumulated Other Comprehensive Income Loss Net Of… | -1 | -1 | 0 | |||||
Retained Earnings Accumulated Deficit | -174 | -151 | -123 | |||||
Stockholders Equity | 814 | 391 | -121 | |||||
Liabilities And Stockholders Equity | 826 | 397 | 153 | |||||
Series A Preferred Stock | - | 0 | 0 | |||||
Series B Preferred Stock | - | 0 | 0 | |||||
Series C Preferred Stock | - | 0 | 0 | |||||
Preferred Stock Par Or Stated Value Per Share | 0 | 0 | - | |||||
Preferred Stock Shares Authorized | 25 | 25 | - | |||||
Preferred Stock Shares Issued | 0 | 0 | - | |||||
Preferred Stock Shares Outstanding | 0 | 0 | - | |||||
Common Stock Par Or Stated Value Per Share | 0 | 0 | 0 | |||||
Common Stock Shares Authorized | 200 | 200 | 267 | |||||
Common Stock Shares Issued | 42 | 37 | 1 | |||||
Shares Outstanding | 42 | 37 | 1 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|
| 2026 | -11.75% | 24.87% | 0.70% | - | - | - | - | - | - |
| 2025 | - | - | - | - | - | - | 11.49% | 67.00% | 54.26% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | |||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Veradermics, Inc (MANE) — SEC Financial Statements & Analysis
Veradermics, Inc (MANE) is a pharmaceutical preparations company, incorporated in DE. Veradermics, Inc trades on NYSE as: MANE. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Veradermics, Inc reported a Debt-to-Equity ratio of 0.01x, a Price-to-Book (P/B) ratio of 6.11x (TTM), at a market cap of $4.97B. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- 0.01x
- P/B TTM
- 6.11x
- Market Cap
- $4.97B
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Veradermics, Inc in?
Veradermics, Inc (MANE) operates in the Pharmaceutical Preparations industry.
What is MANE's market cap?
Veradermics, Inc (MANE) has a market capitalization of $4.97B as of 2026-06-30.
What exchange does MANE trade on?
Veradermics, Inc (MANE) trades on the NYSE.
Where is Veradermics, Inc incorporated?
Veradermics, Inc is incorporated in DE.